Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops ARCUS product for the treatment of acute migrain; rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.
Revenue of Acorda Therapeutics, Inc. (ACOR)
Revenue in 2023 (TTM): $117.63 M
According to Acorda Therapeutics, Inc.'s latest financial reports the company's current revenue (TTM) is $117.63 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Acorda Therapeutics, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $117.63 M | $71.59 M | $8.4 M | $-296,021,000 | $-252,854,000 |
| 2022 | $118.57 M | $88.23 M | $-10,030,000 | $-35,247,000 | $-65,916,000 |
| 2021 | $129.07 M | $88.28 M | $-44,796,000 | $-109,074,000 | $-103,954,000 |
| 2020 | $152.97 M | $119.45 M | $-64,955,000 | $-107,667,000 | $-99,594,000 |
| 2019 | $192.41 M | $157.56 M | $40.18 M | $-274,247,000 | $-272,965,000 |
| 2018 | $471.43 M | $372.12 M | $148.49 M | $20.42 M | $33.68 M |
| 2017 | $588.29 M | $452.57 M | $443.15 M | $-251,885,000 | $-223,359,000 |
| 2016 | $519.6 M | $411.49 M | $16.32 M | $-42,268,000 | $-34,618,000 |
| 2015 | $492.66 M | $399.73 M | $55.79 M | $19.37 M | $11.06 M |
| 2014 | $401.48 M | $320.87 M | $54.77 M | $28.01 M | $17.67 M |
| 2013 | $336.43 M | $269.79 M | $30.37 M | $28.86 M | $16.44 M |
| 2012 | $305.81 M | $248.17 M | $25.6 M | $24.27 M | $154.96 M |
| 2011 | $292.24 M | $225.67 M | $38.09 M | $32.02 M | $30.61 M |
| 2010 | $191.01 M | $155.49 M | $-5,091,000 | $-11,770,000 | $-11,769,000 |
| 2009 | $54.67 M | $43.28 M | $-78,575,000 | $-83,940,242 | $-83,941,000 |
| 2008 | $47.83 M | $36.47 M | $-73,001,492 | $-73,431,269 | $-74,340,640 |
| 2007 | $39.49 M | $31.13 M | $-39,498,104 | $-39,396,598 | $-37,974,467 |
| 2006 | $27.35 M | $20.23 M | $-21,959,805 | $-23,391,488 | $-24,019,372 |
| 2005 | $5.15 M | $13.38 K | $-32,598,535 | $-34,408,489 | $-35,530,247 |
| 2004 | $479.5 K | $-4,822,646 | $-41,699,560 | $-44,764,463 | $-44,740,764 |
| 2003 | $856 K | $856 K | $-61,843,000 | $-63,115,000 | $-62,446,000 |